- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07608458
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
Scheduled Meditation for Perioperative Optimization: A Randomized Controlled Trial on Postoperative Outcomes, Pain, Anxiety, Insomnia, Stress, and Mobility in Pancreatectomy Patients
This clinical trial tests the feasibility and how well a scheduled meditation intervention works to improve postoperative outcomes such as pain, anxiety, insomnia, stress and mobility for patients undergoing pancreatectomy. Many patients undergoing pancreatectomy surgery report clinically important fatigue, pain, and/or reduction in quality of life. Meditation is a behavioral intervention that has been studied in a variety of medical and surgical settings, where it has been associated with reductions in pain, anxiety, blood pressure, and lack of sleep, and in some cases with decreased pain and shorter length of stay. The meditation intervention using Headspace is an easily accessible and interactive way to complete scheduled meditation. This may improve postoperative outcomes for patients undergoing pancreatectomy.
Studieoversikt
Status
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. Evaluate the feasibility of implementing a meditation-based intervention in patients undergoing pancreatectomy, as measured by recruitment, retention, and participant compliance with the prescribed modules II. Evaluate the effect of a perioperative meditation intervention on anxiety, as measured by changes in State-Trait Anxiety Inventory (STAI) scores from baseline to one month postoperatively.
SECONDARY OBJECTIVE:
I. To observe the relationship of meditation intervention on change in health-related quality of life (HRQOL) outcomes for pain and sleep quality from baseline through one month postoperatively.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive access to the Headspace application. Patients complete mindfulness meditation including focused breathing, awareness of thought patterns, and management of mind-wandering for 10 minutes once daily (QD) for 3 weeks prior to surgery and twice daily (BID) for 1 month after surgery. Patients wear a Garmin activity tracker throughout the study.
ARM II: Patients receive access to the Headspace application at the time of hospital discharge and will be informed of the availability of the "Basics" meditation pack. Patients wear a Garmin activity tracker throughout the study.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Duarte, California, Forente stater, 91010
- City of Hope Medical Center
-
Ta kontakt med:
- Bradford Kim
- Telefonnummer: 626-218-1840
- E-post: brakim@coh.org
-
Hovedetterforsker:
- Bradford Kim
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Documented informed consent of the participant and/or legally authorized representative
- Willing to install required apps on personal smartphone
- Willing to wear a Garmin wearable device throughout the study
- Age: ≥ 18 years
- Ability to read and understand English for questionnaires
- Owns a smartphone
- Comfortable with routine smartphone use
- Scheduled to undergo pancreatectomy
Exclusion Criteria:
- Participants with prior formal training in meditation or mindfulness (e.g., completion of structured courses, workshops, or certification programs)
- Participants who currently engage in a structured meditation or mindfulness practice, including regular use of mobile applications (e.g., Headspace, Calm, or similar platforms) or other formalized routines
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm I (Headspace meditation)
Patients receive access to the Headspace application. Patients complete mindfulness meditation including focused breathing, awareness of thought patterns, and management of mind-wandering, for 10 minutes QD for 3 weeks prior to surgery and BID for 1 month after surgery. Patients wear a Garmin activity tracker throughout the study. |
Ancillary studies Wear activity tracker Complete mindfulness mediation
Andre navn:
Receive access to Headspace
Andre navn:
|
|
Eksperimentell: Arm II (Delayed access to Headspace)
Patients receive access to the Headspace application at the time of hospital discharge and will be informed of the availability of the "Basics" meditation pack. Patients wear a Garmin activity tracker throughout the study. |
Ancillary studies Wear activity tracker Complete mindfulness mediation
Andre navn:
Receive access to Headspace
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of enrolled patients who complete the final study assessment (retention)
Tidsramme: Up to 6 months
|
Retention will be considered feasible if ≥ 70% of enrolled participants are retained. Will be estimated along with the 95% exact binomial confidence interval. |
Up to 6 months
|
|
Proportion of prescribed meditation modules completed (compliance)
Tidsramme: Up to 6 months
|
Each participant's proportion of completed meditation modules will be calculated using usage data from the Headspace mobile application. Participants will then be classified as high (> 60%), medium (20-60%), or low (< 20%) compliance. Will be estimated along with the 95% exact binomial confidence interval. |
Up to 6 months
|
|
Change in patient-reported anxiety symptoms
Tidsramme: From baseline up to day 28
|
Measured using the State-Trait Anxiety Inventory (STAI). Response is defined as a reduction of at least 6 points on STAI at date of surgery date relative to baseline. The proportion of participants meeting this threshold will be reported. Will be estimated along with the 95% exact binomial confidence interval. Within-group mean change in STAI will be examined using paired t-tests (comparing any two time points of interest). |
From baseline up to day 28
|
|
Proportion of invited patients who agree to participate (recruitment)
Tidsramme: Up to 6 months
|
Recruitment will be considered feasible if ≥ 50% of eligible patients enroll. Will be estimated along with the 95% exact binomial confidence interval. |
Up to 6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in patient-reported pain - Numeric Rating Scale
Tidsramme: rom the baseline assessment conducted three weeks prior to surgery through one month after surgery.
|
Change in patient-reported pain from baseline three weeks prior to surgery through one month postoperatively, measured using the Numeric Rating Scale (NRS, 0 -10 ). 0 means no pain to 10 means worst pain possible. |
rom the baseline assessment conducted three weeks prior to surgery through one month after surgery.
|
|
Change in patient-reported pain - Brief Pain Inventory
Tidsramme: From the baseline assessment conducted three weeks prior to surgery up to one month after surgery.
|
Change in patient-reported pain from baseline three weeks prior to surgery through one month postoperatively, measured using the Brief Pain Inventory.(BPI). 0 means no pain to 10 means worst pain possible. |
From the baseline assessment conducted three weeks prior to surgery up to one month after surgery.
|
|
Change in patient-reported Pittsburgh Sleep Quality Index (PSQI)
Tidsramme: From baseline up to one month after surgery.
|
Self-reported questionnaire will be used to measure sleep quality and sleep patterns over the past month. PSQI will be interpreted by totaling the component scores into a global score ranging from 0 to 21, where higher scores indicate poorer sleep quality; a score greater than 5 generally suggests significant sleep disturbance or poor sleep quality. |
From baseline up to one month after surgery.
|
|
Change in patient-reported Insomnia Severity Index (ISI)
Tidsramme: From baseline up to one month after surgery.
|
Self-reported questionnaire will be used to assess the severity and impact of insomnia symptoms, including difficulty falling asleep, staying asleep, and the effect of sleep problems on daily functioning. The ISI is interpreted using a total score from 0 to 28: 0-7 indicates no clinically significant insomnia, 8-14 indicates subthreshold insomnia, 15-21 indicates moderate insomnia, and 22-28 indicates severe insomnia. |
From baseline up to one month after surgery.
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Bradford Kim, City of Hope Medical Center
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Neoplasmer etter nettsted
- Neoplasmer
- Neoplasmer etter histologisk type
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Neoplasmer i endokrine kjertel
- Pankreassykdommer
- Galleveissykdommer
- Leversykdommer
- Neoplasmer, kjertel og epitel
- Adenokarsinom
- Neoplasmer i leveren
- Karsinom
- Neoplasmer i galleveiene
- Karsinom, hepatocellulært
- Neoplasmer i bukspyttkjertelen
- Undersøkelsesteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Overvåking, fysiologisk
- Akselerometri
- Aktigrafi
Andre studie-ID-numre
- 25479
- P30CA033572 (U.S. NIH-stipend/kontrakt)
- 25479 (Annen identifikator: City of Hope Medical Center)
- NCI-2026-03206 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .